MX2015012536A - Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc. - Google Patents

Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc.

Info

Publication number
MX2015012536A
MX2015012536A MX2015012536A MX2015012536A MX2015012536A MX 2015012536 A MX2015012536 A MX 2015012536A MX 2015012536 A MX2015012536 A MX 2015012536A MX 2015012536 A MX2015012536 A MX 2015012536A MX 2015012536 A MX2015012536 A MX 2015012536A
Authority
MX
Mexico
Prior art keywords
antiviral agents
direct acting
ribavirin
treatment
acting antiviral
Prior art date
Application number
MX2015012536A
Other languages
English (en)
Inventor
Walid M Awni
Wei Liu
Barry M Bernstein
Thomas J Podsadecki
Sandeep Dutta
Andrew L Campbell
Rajeev M Menon
Chih-Wei Lin
Tianli Wang
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771575&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015012536(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2015012536A publication Critical patent/MX2015012536A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a terapias libres de interferón para el tratamiento del VHC. De preferencia, el tratamiento es de duración corta, tal como no más de 12 semanas. En un aspecto, el tratamiento comprende la administración de por lo menos dos agentes antivirales de acción directa y ribavirina, a un sujeto con una infección por el VHC, en donde el tratamiento dura 12 semanas y no incluye la administración de interferón, y los al menos dos agentes antivirales de acción directa comprenden (a) el Compuesto 1 y (b) el Compuesto 2 o una sal farmacéuticamente aceptable de los mismos, tal como se menciona en la descripción.
MX2015012536A 2013-03-14 2014-03-14 Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc. MX2015012536A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361783437P 2013-03-14 2013-03-14
PCT/US2014/027556 WO2014152635A1 (en) 2013-03-14 2014-03-14 Combination of direct acting antiviral agents and ribavirin for treating hcv patients

Publications (1)

Publication Number Publication Date
MX2015012536A true MX2015012536A (es) 2016-01-12

Family

ID=50771575

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012536A MX2015012536A (es) 2013-03-14 2014-03-14 Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc.

Country Status (27)

Country Link
US (1) US20140274934A1 (es)
EP (4) EP3733180A1 (es)
JP (3) JP6563894B2 (es)
KR (2) KR101853605B1 (es)
CN (3) CN108187056A (es)
AU (3) AU2014239322B2 (es)
BR (1) BR112015020918A2 (es)
CA (1) CA2901818C (es)
CY (1) CY1121474T1 (es)
DK (1) DK2968302T3 (es)
EA (2) EA030482B1 (es)
ES (1) ES2654109T3 (es)
HK (2) HK1213191A1 (es)
HR (1) HRP20171898T1 (es)
HU (1) HUE036069T2 (es)
IL (2) IL240445B (es)
LT (1) LT2968302T (es)
MX (1) MX2015012536A (es)
NO (1) NO3090119T3 (es)
PL (1) PL2968302T4 (es)
PT (1) PT2968302T (es)
RS (1) RS56735B1 (es)
SG (2) SG11201507361YA (es)
SI (1) SI2968302T1 (es)
TW (2) TWI678205B (es)
WO (1) WO2014152635A1 (es)
ZA (1) ZA201705080B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2968302T (pt) * 2013-03-14 2018-01-03 Abbvie Inc Combinação de agentes antivirais de ação direta e ribavirina para tratar pacientes com vhc
WO2015153792A1 (en) * 2014-04-02 2015-10-08 Abbvie Inc. Methods for treating hcv
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
CA2925328A1 (en) * 2013-10-25 2015-04-30 Abbvie, Inc. Methods for treating hcv
EP3082808A1 (en) * 2013-12-19 2016-10-26 AbbVie Inc. Methods for treating liver transplant recipients
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
DE202016009054U1 (de) 2016-01-08 2021-10-11 Entrust Datacard Corporation Kartendruckmechanismus mit Kartenrückführweg
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CA2994496A1 (en) * 2017-02-14 2018-08-14 Abbvie Inc. Methods for treating hcv
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
CN108329332A (zh) * 2018-03-16 2018-07-27 安徽华昌高科药业有限公司 一种制备Glecaprevir的方法
EP3773753A4 (en) * 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2010153688A (ru) * 2008-06-10 2012-07-20 Янссен Фармацевтика Нв (Be) Режим дозирования телапревира
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
UY32699A (es) * 2009-06-11 2010-12-31 Abbott Lab Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv"), procesos, composiciones, y métodos relacionados
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
MX343275B (es) * 2010-09-21 2016-10-31 Enanta Pharm Inc Prolina macrociclica derivada de inhibidores de serina proteasa de vhc.
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
PT2968302T (pt) 2013-03-14 2018-01-03 Abbvie Inc Combinação de agentes antivirais de ação direta e ribavirina para tratar pacientes com vhc

Also Published As

Publication number Publication date
EA030482B1 (ru) 2018-08-31
WO2014152635A9 (en) 2014-12-11
KR101853605B1 (ko) 2018-05-03
EP3318258A1 (en) 2018-05-09
SG10201709840UA (en) 2018-01-30
DK2968302T3 (en) 2017-12-18
PT2968302T (pt) 2018-01-03
TWI678205B (zh) 2019-12-01
EP3733180A1 (en) 2020-11-04
HK1213191A1 (zh) 2016-06-30
IL240445B (en) 2019-07-31
SI2968302T1 (en) 2018-04-30
CA2901818A1 (en) 2014-09-25
EP2968302A1 (en) 2016-01-20
CN105007921B (zh) 2018-12-11
EP2968302B9 (en) 2019-02-13
CY1121474T1 (el) 2020-05-29
PL2968302T3 (pl) 2018-04-30
SG11201507361YA (en) 2015-10-29
CA2901818C (en) 2021-05-04
JP2016513703A (ja) 2016-05-16
ZA201705080B (en) 2019-02-27
LT2968302T (lt) 2017-12-27
HUE036069T2 (hu) 2018-06-28
EP2968302B1 (en) 2017-09-06
AU2018202581A1 (en) 2018-05-10
AU2020201656A1 (en) 2020-03-26
CN109908353A (zh) 2019-06-21
AU2018202581B2 (en) 2019-12-05
HRP20171898T1 (hr) 2018-04-06
EP3318258B1 (en) 2020-05-13
TW202002979A (zh) 2020-01-16
BR112015020918A2 (pt) 2017-07-18
CN105007921A (zh) 2015-10-28
CN108187056A (zh) 2018-06-22
AU2014239322A1 (en) 2015-08-27
JP2019214585A (ja) 2019-12-19
AU2014239322B2 (en) 2018-04-05
EA201890507A1 (ru) 2018-07-31
IL267927A (en) 2019-09-26
JP2019167347A (ja) 2019-10-03
RS56735B1 (sr) 2018-03-30
KR20150129035A (ko) 2015-11-18
NO3090119T3 (es) 2018-03-31
WO2014152635A1 (en) 2014-09-25
KR20180045055A (ko) 2018-05-03
PL2968302T4 (pl) 2018-04-30
EP3915559A1 (en) 2021-12-01
ES2654109T3 (es) 2018-02-12
TW201505633A (zh) 2015-02-16
JP6563894B2 (ja) 2019-08-21
IL240445A0 (en) 2015-09-24
US20140274934A1 (en) 2014-09-18
EA201591701A1 (ru) 2016-02-29
HK1255257A1 (zh) 2019-08-09

Similar Documents

Publication Publication Date Title
MX2020005054A (es) Combinacion de dos agentes antivirales para el tratamiento de hepatitis c.
MX2015012536A (es) Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc.
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
PH12018550201A1 (en) Hepatitis b antiviral agents
PH12014502848A1 (en) Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon
MX2018000240A (es) Metodos para tratar el vhc.
PH12014502847A1 (en) Combination treatment (eg with abt-072-333) of daas for use in treating hcv
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2015017953A (es) Metodos para tratar el virus de hepatitis c.
MX2013003060A (es) Terapia de combinacion para tratar infeccion por hcv.
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
MX2020011107A (es) Regimen de glicosidasa para el tratamiento de enfermedades infecciosas.
PH12017500617A1 (en) Dosage regimen for pegylated interferon
RU2015114566A (ru) Способы лечения гепатита с
MX2020001422A (es) Metodos para el tratamiento de hcv.
MX2018001905A (es) Metodos para el tratamiento del virus de hepatitis c (vhc).
AU2019384793A8 (en) Methods for treating acute HCV
NZ631789A (en) Combination of direct acting antiviral agents and ribavirin for treating hcv patients
WO2014122537A3 (en) Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
EA201491652A1 (ru) Средство для лечения вирусного гепатита с
ES2572355A2 (es) Combinacion de aad para uso en el tratamiento del vhc
EA201892004A1 (ru) Противовирусные средства для лечения гепатита b
TN2013000134A1 (en) Combination therapy for treating hcv infection
UA101772U (uk) Спосіб лікування хронічного вірусного гепатиту с із супутньою неалкогольною жировою хворобою печінки